Our systems, technology, and strategy are specifically designed to achieve High Curative Potential™ (HCP) using the most biologically direct form of immunotherapy: Adoptive (T) Cell Therapy (ACT).
We are committed to developing broadly applicable ACT capable of delivering curative outcomes for the majority of patients treated.
It’s time to Change the Treatment Paradigms for advanced solid cancer.
Curative by Design™
Verik’s team has a forward-looking, yet grounded, perspective on what it will take to make ACT a curative reality for major forms of cancer.
The Verik Team is leading the way once again.
Our SeleCTR™ (Selection of Curative T-cell Receptors) platform is designed to find the cancer proteins and their antigens best suited for High Curative Potential™ (HCP) ACT against solid tumors.
Today, Verik's Pipeline is rich in therapeutic possibilities and could reach well over 100,000 advanced cancer patients annually in the US alone, and our work continues.